REDWOOD CITY, Calif., Oct. 17, 2017 /PRNewswire/ -- Menlo Therapeutics Inc., a late stage biopharmaceutical company, is developinga neurokinin 1 (NK?1) receptor antagonist (serlopitant) for the treatment of pruritus (itch) associated with various underlying conditions, and for the treatment of refractory chronic cough. The company, which continues to advance serlopitant into later
"Adding these key hires is a significant step forward for Menlo Therapeutics as we enter late stage clinical trials for serlopitant. We have built a management team with the skills and experience to bring serlopitant through development to an NDA, if our trials are successful, and experienced in pre-launch commercial planning and strategies in dermatology markets. We are pleased to welcome these accomplished executives to the company and we look forward to leveraging their expertise and industry knowledge to develop serlopitant as a potential treatment option for patients with pruritus, and for those with chronic cough," commented Steven Basta, Chief Executive Officer of Menlo Therapeutics.
About Serlopitant Serlopitant is a once-daily NK1 receptor antagonist being developed for the treatment of pruritus, or itch, associated with atopic dermatitis, psoriasis, and prurigo nodularis. Serlopitant is also being evaluated as a potential treatment option for refractory chronic cough, a cough for which a treatable cause cannot be found. Menlo Therapeutics has completed two Phase 2 studies with serlopitant showing a statistically significant reduction in pruritus compared to placebo. Originally developed by Merck and licensed to Menlo Therapeutics in 2012, serlopitant has been evaluated in more than 1,000 patients and has been shown to be well-tolerated, including in patients who have received treatment for up to a year. Serlopitant is an investigational drug that is not currently approved for use in any indication.
About Menlo Therapeutics Inc.Menlo Therapeutics Inc. is a privately held late stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus associated with various underlying dermatological conditions and refractory chronic cough. The company has initiated a broad clinical development program for serlopitant including Phase 2 studies for the treatment of pruritus associated with atopic dermatitis, pruritus associated with psoriasis, and refractory chronic cough, and expects to start Phase 3 trials for the treatment of pruritus associated with prurigo nodularis in the first half of 2018. Menlo Therapeutics has worldwide rights to serlopitant, excluding Japan where Menlo Therapeutics has licensed serlopitant to JT Torii. Menlo is funded by leading healthcare investors. More information is available at www.menlotherapeutics.com.
View original content:http://www.prnewswire.com/news-releases/menlo-therapeutics-expands-its-management-team-300537670.html
SOURCE Menlo Therapeutics Inc.
Subscribe to our Free Newsletters!
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...View All